A 24-Phenylsulfone Analog of Vitamin D Inhibits 1α,25-Dihydroxyvitamin D3 Degradation in Vitamin D Metabolism-Competent Cells
Authors:
- Teresa ManhardtTMTeresa Manhardt
- Erika BajnaEBErika Bajna
- Gary H. PosnerGPGary H. Posner
- Heide S. CrossHCHeide S. Cross
- 1 March 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 320 (3) , 1119-1126
Abstract
The antimitotic, prodifferentiating, and proapoptotic steroid hormone, 1α,25-dihydroxyvitamin D3 [1α,25-(OH)2D3], at supraphysiological levels has potential for tumor therapy. However, epithelial cells from tumor-prone organs such as colon, prostate, and breast express not only the vitamin D receptor, but also vitamin D hydroxylases. In contrast to normal cells, malignant cells have high basal levels of the hydroxylase 25-hydroxyvitamin D3-24-hydroxylase (CYP24) and, in addition, have the potential to induce CYP24 in response to 1α,25-(OH)2D3. Because 24-hydroxylation by CYP24 would rapidly degrade the steroid hormone in the course of therapy, the enzyme activity in tumor cells should be inhibited. We demonstrate that a 24-phenylsulfone analog of 1α,25-(OH)2D3, KRC-24SO2Ph-1 (S-4a), rapidly and potently inhibits 24-hydroxylase activity in human tumor cells derived from colon, prostate, and mammary gland. Although enzymatic inhibition is a consequence of direct interaction, S-4a as a vitamin D analog apparently binds to the vitamin D receptor and induces CYP24 mRNA, which, however, is not translated into increased enzymatic activity. 25-Hydroxyvitamin D3-1α-hydroxylase expression is not affected at all by S-4a. When both 1α,25-(OH)2D3 and S-4a are added to the cell culture, transcription of CYP24 is increased, possibly because of an increase in the half-life of the hormone. The colon cell line COGA-13 has very high levels of CYP24 and is, therefore, resistant to the action of vitamin D. Yet, S-4a imparts antimitotic activity to 1α,25-(OH)2D3 and may therefore constitute a therapeutic to stimulate the antiproliferative potential of vitamin D-based antitumor activity.Keywords
This publication has 38 references indexed in Scilit:
- The Vitamin D endocrine system of the gut—Its possible role in colorectal cancer preventionThe Journal of Steroid Biochemistry and Molecular Biology, 2005
- 25-Hydroxyvitamin D3-1α-hydroxylase Expression in Normal and Malignant Human ColonJournal of Histochemistry & Cytochemistry, 2004
- 25-Hydroxy-Vitamin D Metabolism in Human Colon Cancer Cells during Tumor ProgressionBiochemical and Biophysical Research Communications, 2001
- 25-Hydroxyvitamin D3-1α-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesisSteroids, 2001
- 1α,25-Dihydroxy-3-epi-vitamin D3 a physiological metabolite of 1α,25-dihydroxyvitamin D3: Its production and metabolism in primary human keratinocytesMolecular and Cellular Endocrinology, 2000
- Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)Cancer Causes & Control, 2000
- Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogeneNature Genetics, 2000
- EFFICACY OF MICROTUBULE-ACTIVE DRUGS FOLLOWED BY KETOCONAZOLE IN HUMAN METASTATIC PROSTATE CANCER CELL LINESJournal of Urology, 2000
- Differentiation-Related Pathways of 1α,25-Dihydroxycholecalciferol Metabolism in Human Colon Adenocarcinoma-Derived Caco-2 Cells: Production of 1α,25-Dihydroxy-3epi-cholecalciferolExperimental Cell Research, 1998
- Differentiation of breast cancer cells in vitro is promoted by the concurrent influence of myoepithelial cells and relaxinBritish Journal of Cancer, 1994